Carlos Rojas, MD, discusses the next steps for evaluating MK-1084 in a phase 1 trial for the first-line treatment of metastatic non-small cell lung cancer and advanced solid tumors.
Mikkael Sekeres, MD, discusses a phase 2 study of pevonedistat plus azacitidine versus azacitadine monotherapy in patients with higher-risk myelodysplastic syndromes /chronic myelomonocytic leukemia or low-blast acute myelogenous leukemia.
Jerald P. Radich, MD, discusses how minimal residual disease is measured in hematologic malignancies.
Nicholas J. Robert, MD, discusses a study of the social determinants of a patient’s health related to the use of genomic testing in women with breast cancer.
Hedyeh Ebrahimi, MD, MPH, discusses a study that found adding the live bacterial product CBM588 to standard immunotherapy potentially impacted patients' responses in renal cell carcinoma.
In heavily pretreated patients with recurrent low-grade serous ovarian cancer, the combination of avutometinib plus defactinib showing promising results within the phase 2 ENGOT-ov60/GOG-3052/RAMP 201 trial.
Senthil Damodaran, MD, PhD, discusses data from a phase 2 trial of futibatinib in patients with metastatic HR-positive/HER2-negative breast cancer with FGFR1 amplifications.
Just-in-time trials are 1 tool capable of rapidly increasing access to clinical trials to develop drugs that treat the diverse and unique tapestry of patients across the United States, especially patients with more diverse racial, ethnic, and socioeconomic backgrounds.
Nancy U. Lin, MD, discusses the results from a substudy of HER2CLIMB looking at tucatinib plus trastuzumab and capecitabine in patients with HER2-positive breast cancer and brain metastases.
Benjamin Besse, MD, PhD, discusses the biomarker analysis of the phase 1/1b CHRYSALIS-2 study of amivantamab and lazertinib in patients with EGFR-mutated non–small cell lung cancer.
Orca-T demonstrated survival rates vs post-transplant cyclophosphamide in patients with hematologic malignancies receiving myeloablative conditioning, according to findings from a retrospective analysis.
Heinz Ludwig, MD, discusses the incidence of increased infections in patients with multiple myeloma.
Christine Dierks, MD, describes the prognosis of the anaplastic thyroid carcinoma and differentiated thyroid cancer populations.
Nicolaus Kröger, MD, discusses the advantages of autologous stem cell transplant and allogeneic stem cell transplant compared with autologous tandem transplant in patients with multiple myeloma.
The potential benefit of avelumab in the subgroup of patients with high PD-L1 expression in JAVELIN HEAD AND NECK 100 provides a basis for further investigation and suggests a potential role for immune checkpoint inhibitors for locally advanced HNSCC.
Bruno Sangro, MD, PhD, discusses the key takeaways from recent data in the treatment landscape of patients with hepatocellular carcinoma.
Thomas Habermann, MD, discusses the unmet clinical needs which still exist for patients with diffuse large B-cell lymphoma.
Charles Meakin, MD, MHA, chief medical officer of Care Oncology, discusses the current colorectal cancer landscape, innovations in detection, and improving patient screening and follow-up care for Colorectal Cancer Awareness Month.
Rebecca A. Shatsky, MD, discusses the advantages of giving patients with HER2-positive breast cancer a subcutaneous injection of targeted therapy compared with the intravenous formulation of trastuzumab and pertuzumab.
Artificial intelligence and machine learning dramatically alter how medicine is practiced, and cancer detection is no exception, according to Toufic Kachaamy, MD of City of Hope Phoenix.
Efstathios Kastritis, MD, discusses the amyloidosis setting, current standards of care, and the phase 3 ANDROMEDA trial.
Research shows that methods used to treat the wide epidermal growth factor receptor-positive population are often not successful for patients with specific biomarkers like EGFR exon 20 insertion mutations, highlighting an ongoing need for more targeted therapies.
The Florida Cancer Specialists & Research Institute's Data Governance Committee was established to oversee the program’s implementation and monitor its progress.
Michael T. Tees, MD, discusses the data behind ALLO-501A, an allogeneic chimeric antigen receptor T-cell therapy for relapsed or refractory large B-cell lymphoma.
Prerna Mewawalla, MD, discusses how the treatment landscape for multiple myeloma is growing.
Chad A. Hamilton, MD, offers closing thoughts on the future outlook and unmet needs in the ovarian cancer treatment landscape.
William H. Bradley, MD, discusses the 5-year follow-up of the SOLO-1 trial of olaparib maintenance in patients with BRCA1/2-mutated advanced ovarian cancer.
Matthew J. Frigault, MD, MS, discussed what a community oncologist should know about the ongoing FDA investigation of chimeric antigen receptor T-cell therapies.